Cystic fibrosis: Review of the decade

Monaldi Archives for Chest Disease

Volumn 56, Issue 3, 2001, Pages 240-247

  Jaffe A ^a   Bush, A ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cystic fibrosis; Review

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; DEOXYRIBONUCLEASE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; PREDNISONE; STEROID;

BACTERIUM ADHERENCE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GENE MUTATION; GENE THERAPY; GENETIC CODE; HUMAN; ION TRANSPORT; LIFE EXPECTANCY; LUNG DISEASE; LUNG TRANSPLANTATION; NEWBORN SCREENING; NUTRITION; ORGAN DONOR; PATHOPHYSIOLOGY; PATIENT REFERRAL; PHYSIOTHERAPY; REHABILITATION CENTER; REVIEW; SIDE EFFECT; SURVIVAL;

EID: 0034784660     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Incidence, population and survival of cystic fibrosis in the UK, 1968-95
2. Cystic fibrosis: Current survival and population estimates to the year 2000
3. Identification of the cystic fibrosis gene: Chromosome walking and jumping
4. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
5. Identification of the cystic fibrosis gene: Genetic analysis
6. A cystic fibrosis mutation associated with mild lung disease
7. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop codons
8. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations
9. A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in ΔF508-homozygous cystic fibrosis patients
10. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport
11. Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator
12. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP
13. Nasal potential difference: A clinical diagnostic test for cystic fibrosis
14. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium
15. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: A double-blind placebo-controlled trial
16. Abnormal ion permeation through cystic fibrosis respiratory epithelium
17. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis
18. Confirmation of abnormal chloride ion secretion in the lower airway of children with cystic fibrosis
19. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid
20. Human β-Defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis
21. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects
22. Ion transport properties of human fetal tracheal epithelial cells in primary cultures
23. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections
24. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung
25. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium
26. Cardiopulmonary physiology
27. Early pulmonary inflammation in infants with cystic fibrosis
28. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis
29. Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention
30. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells
31. Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells
32. Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology
33. Inflammation and infection in naive human cystic fibrosis airway grafts
34. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp
35. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic
36. Pseudomonas cepacia colonization in patients with cystic fibrosis: Risk factors and clinical outcome
37. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group
38. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis
39. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic
40. Acquiring stenotrophomonas maltophilia does not reduce survival in patients with cystic fibrosis
41. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period
42. Prophylactic antibiotics for cystic fibrosis
43. Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis
44. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis
45. Management of pulmonary disease in patients with cystic fibrosis
46. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
47. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
48. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs
49. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis
50. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group
51. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study
52. Advantages of colistin dry powder inhalation: Proof of principle
53. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis
54. Risks of alternate-day prednisone in patients with cystic fibrosis
55. Paradoxic effect of ibuprofen on neutrophil accumulation in pulmonary and cutaneous inflammation
56. Effect of high-dose ibuprofen in patients with cystic fibrosis
57. Diffuse panbronchiolitis and cystic fibrosis: East meets
58. Diffuse panbronchiolitis in an Asian immigrant
59. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis
60. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: A potential mechanism of macrolide therapy
61. Diffuse panbronchiolitis: Efficacy of low-dose erythromycin
62. Long-term azithromycin may improve lung function in children with cystic fibrosis
63. Active cycle of breathing technique versus external high frequency oscillations in cystic fibrosis
64. Forced expiratory manoeuvres to increase transport of bronchial mucus: A mechanistic approach
65. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: Analysis of the Cystic Fibrosis Foundation National CF Patient Registry
66. Relation of thickening of colon wall to pancreatic-enzyme treatment in cystic fibrosis
67. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes
68. Parental attitudes toward newborn screening for cystic fibrosis
69. Genetic and clinical features of patients with cystic fibrosis diagnosed after 16 years
70. Dried-blood spot screening for cystic fibrosis in the newborn
71. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis
72. Screening for cystic fibrosis
73. Neonatal screening for cystic fibrosis
74. Neonatal screening for cystic fibrosis in Wales and the West Midlands: Clinical assessment after five years of screening
75. Long term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre
76. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group
77. Clinical outcomes of newborn screening for cystic fibrosis
78. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis
79. Neonatal screening for cystic fibrosis in Brittany, France: Assessment of 10 years experience and impact on prenatal diagnosis
80. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum
81. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis
82. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
83. Retrospective review of the effects of rhDNase in children with cystic fibrosis
84. A randomized placebo-controlled trial of two years treatment with dornase alpha (pulmozyme) in cystic fibrosis patients aged 6-10 years with early lung disease
85. Cystic fibrosis in the mouse by targeted insertional mutagenesis
86. Production of a severe cystic fibrosis mutation in mice by gene targeting
87. An animal model for cystic fibrosis made by gene targeting
88. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice
89. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial
90. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
91. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
92. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis
93. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis
94. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus
95. Heart-lung transplantation for cystic fibrosis
96. Heart-lung transplantation for cystic fibrosis and subsequent domino heart transplantation
97. Long term results of lung transplantation for cystic fibrosis
98. Comparison of outcomes between living donor and cadaveric lung transplantation in children
99. Clinical outcome in relation to care in centres specialising in cystic fibrosis: Cross sectional study